Literature DB >> 7640044

High-dose carboplatin and etoposide for salvage chemotherapy of germ cell tumours.

H Lampe1, D P Dearnaley, A Price, J Mehta, R Powles, J Nicholls, A Horwich.   

Abstract

We evaluated high-dose carboplatin and etoposide with autologous bone marrow stem cell support in the salvage treatment of patients with metastatic germ cell tumours who had failed previous chemotherapy. The treatment programme comprised initial conventional dose chemotherapy. 23 patients received a first cycle of high-dose treatment, and 12 who showed no evidence of progression had a second cycle 2-3 months later. 8 of the 23 patients treated with high-dose chemotherapy are alive in remission 4-29 months from the start of high-dose treatment. 3 of these 8 required further treatment for recurrence. In the initial part of the study, the dose of carboplatin was escalated in successive patients. Grade 3/4 treatment-related toxicity occurred in 4 of 18 patients (1 fatal) who received carboplatin doses to give a AUC (area under the serum concentration/time curve) of 30 mg.min/ml or less and 3 of 5 patients (2 fatal) who received higher doses. We, therefore, recommend 30 mg.min/ml for further evaluation in chemotherapy sensitive patients.

Entities:  

Mesh:

Substances:

Year:  1995        PMID: 7640044     DOI: 10.1016/0959-8049(95)00018-e

Source DB:  PubMed          Journal:  Eur J Cancer        ISSN: 0959-8049            Impact factor:   9.162


  3 in total

1.  Salvage treatment for testicular cancer with standard- or high-dose chemotherapy: a systematic review of 59 studies.

Authors:  Fausto Petrelli; Andrea Coinu; Giovanni Rosti; Paolo Pedrazzoli; Sandro Barni
Journal:  Med Oncol       Date:  2017-06-26       Impact factor: 3.064

Review 2.  Diagnosis and treatment of patients with testicular germ cell cancer.

Authors:  J T Hartmann; L Kanz; C Bokemeyer
Journal:  Drugs       Date:  1999-08       Impact factor: 9.546

3.  Fertility, gonadal and sexual function in survivors of testicular cancer.

Authors:  R A Huddart; A Norman; C Moynihan; A Horwich; C Parker; E Nicholls; D P Dearnaley
Journal:  Br J Cancer       Date:  2005-07-25       Impact factor: 7.640

  3 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.